Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
GlobeNewswireApr 25 09:00 ET
Opthea Limited Issues New Contractor Options
TipRanksApr 14 23:17 ET
Owning 39% Shares,institutional Owners Seem Interested in Opthea Limited (ASX:OPT),
Yahoo FinanceApr 12 16:49 ET
Opthea Hires New VP to Advance Retinal Therapies
TipRanksApr 8 18:57 ET
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
GlobeNewswireApr 8 18:42 ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Ultragenyx Pharmaceutical (RARE) and Opthea Limited Sponsored ADR (OPT)
TipRanksApr 8 03:40 ET
Opthea Limited Foresees Visionary Breakthroughs
TipRanksApr 4 19:37 ET
Opthea to Participate in the 23?? Annual Needham Virtual Healthcare Conference
Globe NewswireApr 4 18:34 ET
Opthea Limited Announces Director's Resignation and Final Interests
TipRanksApr 4 03:57 ET
Opthea Limited Welcomes New Director
TipRanksApr 4 03:27 ET
Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea Shares Are Falling Today
The Motley FoolApr 3 22:19 ET
Opthea Bolsters Board With Biopharmaceutical Expertise
TipRanksApr 3 22:07 ET
Opthea Limited Foresees Growth in Vision Therapy
TipRanksApr 3 18:07 ET
Press Release: Opthea Appoints Sujal Shah to the Board of Directors
Opthea Appoints Sujal Shah to the Board of Directors Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair
Dow JonesApr 3 17:39 ET
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly
GlobeNewswireMar 19 06:00 ET
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; "Opthea"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevale
GlobeNewswireMar 5 17:08 ET
Buy Rating for Opthea Limited on Promising Phase 2b Results of Sozinibercept for Wet AMD
TipRanksFeb 29 06:28 ET
Opthea Reports 2H Results
Seeking AlphaFeb 29 02:52 ET
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump
Opthea (ASX:OPT) reported Thursday that it narrowed its loss per share in the six-month period ended Dec. 31, 2023, to $0.1623 from the prior-year period's $0.1651. However, loss for the period widene
MT NewswiresFeb 28 19:15 ET
Express News | Opthea Reports $157.1M In Cash And Cash Equivalents, As Of December 31, 2023; Provides Business Updates
Moomoo 24/7Feb 28 17:58 ET
No Data
No Data